This MedLibrary.org supplementary page on Piperacillin-tazobactam is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Piperacillin
|
|
| Systematic (IUPAC) name | |
| (2S,5R,6R)-6-{[(2R)-2-[(4-ethyl-2,3-dioxo-piperazine- 1-carbonyl)amino]-2-phenyl-acetyl]amino}-3,3-dimethyl- 7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
|
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C23H26N5O7S |
| Mol. mass | 516.548 g/mol |
| Pharmacokinetic data | |
| Bioavailability | not absorbed orally |
| Metabolism | largely not metabolised |
| Half life | 36–72 minutes |
| Excretion | 20% in bile, 80% unchanged in urine |
| Therapeutic considerations | |
| Pregnancy cat. |
B |
| Legal status | |
| Routes | IV, IM |
Piperacillin is an extended spectrum beta-lactam antibiotic of the ureidopenicillin class. It is normally used together with a beta-lactamase inhibitor such as tazobactam, which is commercially available as Tazocin, Zobactin or Zosyn. The combination has activity against many Gram-positive and Gram-negative pathogens and anaerobes, including Pseudomonas aeruginosa.
Piperacillin is not absorbed orally, and must therefore be given by intravenous or intramuscular injection; piperacillin/tazobactam is administered intravenously every 6 or 8 hours; the drug may also be given by continuous infusion, but this has not been shown to be superior.[1] Its main uses are in intensive care medicine (pneumonia, peritonitis), some diabetes-related foot infections and empirical therapy in febrile neutropenia (e.g. after chemotherapy).
Trade names and preparations
Piperacillin alone:
- Pipracil (U.S. only)
Piperacillin/tazobactam:
- Tazocin (UK, marketed by Wyeth)
- Tazocin (Japan, marketed by Toyama)
- Tazocin (New Zealand, marketed by Wyeth)
- Zosyn (U.S., marketed by Wyeth)
- Zobactin (India, marketed by GSK)
References
- ^ Lau W, Mercer D, Itani K, et al. (2006). "Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection". Antimicrob Agents Chemother 50 (11): 3556–61. doi:. PMID 16940077.
External links
- Zosyn (piperacillin/tazobactam combination) - information for U.S.
- Tazocin data sheet for New Zealand
 |
This molecular or cell biology article is a stub. You can help Wikipedia by expanding it. |
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
Wikipedia content modification information:
- This page was last modified on 3 August 2008, at 13:52.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Piperacillin-tazobactam".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.